Xcell Biosciences, Inc. (“Xcellbio”), a leading developer of innovative technologies and platforms designed to further the research, development, and manufacturing of cell and gene therapies, today announced $27.5 million in Series B financing led by Casdin Capital. Also participating in this financing are new investors Dynamk Capital, Formic Ventures, and Labcorp, as well as existing investors HBM Genomics and Viking Global Investors. In connection with the financing, Shaun Rodriguez, PhD, Director of Life Science Research at Casdin Capital, will join the Xcellbio board of directors.